Change in body mass index and insulin resistance after 1-year treatment with gonadotropin-releasing hormone agonists in girls with central precocious puberty

PURPOSE: Gonadotropin-releasing hormone agonist (GnRHa) is used as a therapeutic agent for central precocious puberty (CPP); however, increased obesity may subsequently occur. This study compared body mass index (BMI) and insulin resistance during the first year of GnRHa treatment for CPP. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jina, Kim, Jae Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Pediatric Endocrinology 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401819/
https://www.ncbi.nlm.nih.gov/pubmed/28443256
http://dx.doi.org/10.6065/apem.2017.22.1.27

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401819/
https://www.ncbi.nlm.nih.gov/pubmed/28443256
http://dx.doi.org/10.6065/apem.2017.22.1.27

Ejemplares similares